Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release, titled Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint.
Sun Pharmaceutical Industries Limited Press Release Jul 21 2025
Filed with NSE · · 5 pages · English
Watch Sun Pharmaceutical Industries' latest callSun Pharmaceutical Industries (NSE:SUNPHARMA) Q2 2027 Earnings Call · Replay · Oct 30Read the transcript of Sun Pharmaceutical Industries (NSE:SUNPHARMA) Q2 2027 Earnings CallRelease
Sun Pharmaceutical Industries Limited on 6ix
Earlier from Sun Pharmaceutical Industries
- Sun Pharma Announces Appointment of Richard Ascroft as CEO North America
- Press Release Jun 24 2025
- Sun Pharma appoints Kirti Ganorkar as the Managing Director, Dilip Shanghvi to continue as the Executive Chairman of the Board
- Pharmazz Inc. Secures $25 Million Strategic Equity Investment from Sun Pharmaceutical Industries Ltd.
- Press Release Jun 03 2025
Later from Sun Pharmaceutical Industries
- Mallinckrodt Names Dr. Marek J. Honczarenko as EVP and Chief Scientific Officer
- Sun Pharma Announces Jeremy Allen as Vice President, Corporate Affairs for North America
- Sun Pharmaceutical Industries Limited Press Release Nov 12 2025
- Sun Pharma Canada Inc. Acquires Commercial Rights to LEVULAN® KERASTICK®
- Press Release Nov 17 2025
Follow Sun Pharmaceutical Industries into a list and get an email when it puts out news.
Follow Sun Pharmaceutical Industries